₹-1.85
(Market cap
₹5,940 Cr
Recently Viewed
Clear AllMarket cap
₹5,940 Cr
Revenue (TTM)
₹2,078 Cr
P/E Ratio
27.4
P/B Ratio
2.4
Div. Yield
1.4 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹217 Cr
ROE
12.2 %
ROCE
16.5 %
Industry P/E
29.53
EV/EBITDA
15.8
Debt to Equity
0
Book Value
₹151.1
EPS
₹14.3
Face value
1
Shares outstanding
162,810,084
CFO
₹1,903.42 Cr
EBITDA
₹2,723.52 Cr
Net Profit
₹2,223.42 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
FDC
| -13.7 | 13.7 | -0.5 | -14.2 | 8.3 | 3.5 | 7.3 |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
FDC
| -17.2 | 26.7 | 46.4 | -11.0 | -8.6 | 56.1 | 22.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
FDC
|
365.2 | 5,940.1 | 2,078.0 | 216.7 | 10.6 | 9.9 | 27.4 | 2.4 |
| 2,756.0 | 34,418.5 | 5,201.6 | 1,014.6 | 22.9 | 25 | 33.9 | 7.5 | |
| 8,465.5 | 21,144.6 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.3 | 25.4 | |
| 1,732.2 | 13,164.9 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.5 | 4.0 | |
| 1,327.6 | 18,343.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.5 | 5.1 | |
| 2,043.6 | 32,811.8 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.5 | 8.2 | |
| 4,820.1 | 22,031.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 5,112.9 | 8,480.8 | 1,348.5 | 293.5 | 28.1 | 50.7 | 28.9 | 12.2 | |
| 407.8 | 7,980.7 | 1,432.0 | 149.0 | 19.1 | 7.9 | 53.2 | 3.2 | |
| 1,052.0 | 9,701.6 | 4,725.6 | 528.7 | 14.9 | 20.7 | 19 | 3.3 |
1 min read•By Dhruv Singhvi
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including... anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India. Read more
Incorporated
1940
Chairman
--
Managing Director
Mohan A Chandavarkar
Headquarters
Chhatrapati Sambhajinagar - (Aurangabad), Maharashtra
Website
Looking for more details about FDC Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of FDC Ltd is ₹365.20 (NSE) and ₹364.85 (BSE) as of 28-Apr-2026 IST. FDC Ltd has given a return of 8.32% in the last 3 years.
The P/E ratio of FDC Ltd is 27.41 times as on 28-Apr-2026, a 7 discount to its peers’ median range of 29.53 times.
The P/B ratio of FDC Ltd is 2.42 times as on 28-Apr-2026, a 47 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
24.06
|
2.81
|
|
2024
|
22.66
|
3.30
|
|
2023
|
21.94
|
2.15
|
|
2022
|
20.04
|
2.22
|
|
2021
|
16.00
|
2.78
|
The 52-week high and low of FDC Ltd are Rs 527.80 and Rs 312.95 as of 28-Apr-2026.
FDC Ltd has a market capitalisation of ₹ 5,940 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in FDC Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.